Solactive AG has launched the Solactive Pharma & Biotech Opportunity Index, which will be used as underlying by Societe Generale Corporate & Investment Banking (SG CIB) for an Open End Certificate targeting IFAs as well as clients in retail and private banking based both in Germany and Austria.
The Solactive Pharma & Biotech Opportunity Index aims to capture growth of the consolidating pharmaceutical and biotechnology healthcare industry, through companies which are potential targets of M&A activity.
Steffen Scheuble, CEO at Solactive, said: “Being close to the market, following the latest trends and launching first of their kinds indices is key to an Index Provider. The Solactive Pharma & Biotech Opportunity Index is a great example of an innovative idea with a huge potential — tracking stocks in the growing pharma & biotech industry whose price would benefit from the premium paid if they do get acquired.”
Peter Bösenberg, director and head of Public Distribution Germany & Austria at SG CIB ads: “Through the new Open End Certificate on the Pharma & Biotech Opportunity-Index, Investors have an interesting opportunity to benefit from the increasing M&A Activity in terms of the consolidation of the Pharma & Biotech Industry.”